DRKS00012884招募中不适用
EU-Wide Cross-Sectional Observational Study ofLipid-Modifying Therapy Use in Secondary andPrimary Care DA VINCI - DA VINCI
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- Amgen Ltd
- 入组人数
- 6,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Inclusion Criteria
- •LDL-C measurement within 14 months of enrolment, obtained independently of
- •participation in a clinical trial
- •Use of any LMT (may include statin/ezetimibe/fibrate/PCSK9 inhibitor/bile acid
- •absorption inhibitor/nicotinic acid/other) at time of enrolment, or any LMT
- •prescribed within 12 months prior to date of enrolment, or any LMT prescribed at
- •date of enrolment
- •Age = 18 years at enrolment
- •Provided informed consent/notified according to local requirements
- •Subject expected to survive for at least 1 year after enrolment
排除标准
- •Exclusion Criteria
- •Diagnosis of FH and with history of CV event
- •Currently receiving therapy for carcinoma (excepting squamous epithelial cell)
- •Known HIV positive status
- •Pregnant or breastfeeding at time of enrolment
- •Participating in an interventional clinical trial within 6 months prior to enrolment
研究者
相似试验
进行中（未招募）
不适用
A Pan-European, open label, randomised study comparing the efficacy and cost-effectiveness of Symbicort Maintenance and Reliever Therapy (Symbicort SMART) using a maintenance dose of Symbicort 160/4.5 micrograms of 1 or 2 inhalations twice daily in the treatment of persistent asthma. EUROSMART - EUROSMARTPersistent asthma.MedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2006-006512-30-DKAstraZeneca AB8,250
进行中（未招募）
1 期
A Pan-European, open label, randomised study comparing the efficacy and cost-effectiveness of Symbicort Maintenance and Reliever Therapy (Symbicort SMART) using a maintenance dose of Symbicort 160/4.5 micrograms of 1 or 2 inhalations twice daily in the treatment of persistent asthma. EUROSMART - EUROSMARTPersistent asthma.MedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2006-006512-30-GRAstraZeneca AB8,250
进行中（未招募）
1 期
A Pan-European, open label, randomised study comparing the efficacy and cost-effectiveness of Symbicort Maintenance and Reliever Therapy (Symbicort SMART) using a maintenance dose of Symbicort 160/4.5 micrograms of 1 or 2 inhalations twice daily in the treatment of persistent asthma. EUROSMART - EUROSMARTEUCTR2006-006512-30-GBAstraZeneca AB8,250
进行中（未招募）
不适用
A Pan-European, open label, randomised study comparing the efficacy and cost-effectiveness of Symbicort Maintenance and Reliever Therapy (Symbicort SMART) using a maintenance dose of Symbicort 160/4.5 micrograms of 1 or 2 inhalations twice daily in the treatment of persistent asthma. EUROSMART - EUROSMARTEUCTR2006-006512-30-ISAstraZeneca AB8,250
进行中（未招募）
1 期
A Pan-European, open label, randomised study comparing the efficacy and cost-effectiveness of Symbicort Maintenance and Reliever Therapy (Symbicort SMART) using a maintenance dose of Symbicort 160/4.5 micrograms of 1 or 2 inhalations twice daily in the treatment of persistent asthma. EUROSMART - EUROSMARTPersistent asthma.MedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2006-006512-30-FRAstraZeneca AB8,250